Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Is this the catalyst US tech gian needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,114.00 | 7.00 | 0.08% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,634.14 | 259.40 | -1.00% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,409.87 | 514.24 | -0.90% |
| NZX 50 Index | 12,963.10 | 218.34 | -1.66% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,924.10 | 12.30 | 0.14% |
| SSE Composite Index | 3,981.36 | 4.86 | -0.12% |